Lynn Francesconi

Title: Lynn Francesconi: Innovator in Targeted PET Imaging

Introduction

Lynn Francesconi is a notable inventor based in Bridgewater, NJ (US). He has made significant contributions to the field of medical imaging, particularly in the development of compositions for therapeutics and targeted PET imaging.

Latest Patents

Francesconi holds a patent for "Compositions for therapeutics, targeted PET imaging and methods of their use." This patent describes a chelator for radiolabels, such as Zirconium (Zr), which serves as an alternative to DFO. The ligand, 3,4,3-(LI-1,2-HOPO) ('HOPO'), demonstrates equal or superior stability compared to DFO in various chemical and biological assays over several days in vivo. The HOPO acts as an octadentate chelator that stabilizes the chelation of radiolabels. Additionally, a bifunctional ligand comprising p-SCN-Bn-HOPO is designed to minimize the loss of Zr from the chelate in vivo, thereby enhancing the safety and efficacy of PET imaging with radiolabeled antibodies.

Career Highlights

Francesconi has worked with prestigious institutions, including Memorial Sloan Kettering Cancer Center and City University of New York. His work has focused on advancing the field of radiochemistry and improving imaging techniques for better diagnostic outcomes.

Collaborations

Some of his notable coworkers include Jason S. Lewis and Melissa Deri, who have contributed to his research endeavors.

Conclusion

Lynn Francesconi's innovative work in targeted PET imaging and his patent contributions highlight his role as a key figure in advancing medical imaging technologies. His research continues to pave the way for safer and more effective diagnostic methods.